Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Hye Min Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2899-9480; OpenAlex author ID A5100698493. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers · 2025: 1 paper

Papers 10

  1. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2025.1999↗
  2. Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinical application in pancreatic ductal adeno… Co-author DOI 10.1016/j.gie.2024.02.021↗
  3. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma an… Co-author DOI 10.1186/s12943-024-02003-0↗
  4. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression First author DOI 10.1101/2023.02.15.23286007↗
  5. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12967-023-04549-x↗
  6. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression Co-author DOI 10.21203/rs.3.rs-2578124/v1↗
  7. Anti-cancer effects of metformin in a 3D co-culture model of pancreatic ductal adenocarcinoma. Co-author PMID 37293149↗
  8. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2021.101321↗
  9. Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy. First author DOI 10.3390/cancers13112791↗
  10. Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker. Co-author DOI 10.3389/fonc.2020.616440↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kyu Taek Lee · 9 shared papers, 2020–2025 · strength 1.30
  2. Joo Kyung Park · 9 shared papers, 2020–2025 · strength 1.30
  3. Jong Kyun Lee · 6 shared papers, 2022–2025 · strength 0.91
  4. Kee‐Taek Jang · 4 shared papers, 2021–2025 · strength 0.65
  5. Young Hoon Choi · 4 shared papers, 2023–2025 · strength 0.60
  6. Jin Ho Choi · 3 shared papers, 2024–2025 · strength 0.53
  7. Kwang Hyuck Lee · 4 shared papers, 2020–2023 · strength 0.52
  8. Youngil Koh · 3 shared papers, 2023 · strength 0.42
  9. Hyung Rae Kim · 3 shared papers, 2023 · strength 0.42
  10. Sung‐Soo Yoon · 3 shared papers, 2023 · strength 0.42
  11. Daechan Park · 3 shared papers, 2023 · strength 0.42
  12. In Woong Han · 2 shared papers, 2023–2025 · strength 0.38
  13. Sang Hyun Shin · 2 shared papers, 2023–2025 · strength 0.38
  14. Semin Lee · 2 shared papers, 2024 · strength 0.35
  15. Hongbeom Kim · 2 shared papers, 2020–2025 · strength 0.28
  16. Jong Kyun Lee · 2 shared papers, 2020–2024 · strength 0.28
  17. Jin‐Young Jang · 2 shared papers, 2023 · strength 0.28
  18. Kwang Hyuck Lee · 2 shared papers, 2021–2023 · strength 0.25
  19. Jin‐Young Jang · 2 shared papers, 2020–2023 · strength 0.24
  20. Jae Hyeon Kim · 1 shared paper, 2023 · strength 0.19
  21. Sang‐Man Jin · 1 shared paper, 2023 · strength 0.19
  22. Soojung Hahn · 1 shared paper, 2023 · strength 0.19
  23. So Jeong Yoon · 1 shared paper, 2025 · strength 0.18
  24. Jin Seok Heo · 1 shared paper, 2025 · strength 0.18
  25. Kyunga Kim · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.